Yuan Guan1, Xinyu Chen1, Manhong Wu1, Wan Zhu1, Ahmed Arslan1, Saori Takeda1, Mindie H Nguyen2, Ravindra Majeti3, Dan Thomas3, Ming Zheng1, Gary Peltz4. 1. Department of Anesthesia, Stanford University School of Medicine, Stanford, CA 94305. 2. Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305. 3. Department of Medicine, Division of Hematology, Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine. 4. Department of Anesthesia, Stanford University School of Medicine, Stanford, CA 94305. Electronic address: gpeltz@stanford.edu.
Abstract
BACKGROUND & AIMS: Since human induced pluripotent stem cells (iPSCs) develop into hepatic organoids through stages that resemble human embryonic liver development, they can be used to study developmental processes and disease pathology. Therefore, we examined the early stages of hepatic organoid formation to identify key pathways affecting early liver development. METHODS: Single-cell RNA-sequencing and metabolomic analysis was performed on developing organoid cultures at the iPSC, hepatoblast (day 9) and mature organoid stage. The importance of the phosphatidylethanolamine biosynthesis pathway to early liver development was examined in developing organoid cultures using iPSC with a CRISPR-mediated gene knockout and an over the counter medication (meclizine) that inhibits the rate-limiting enzyme in this pathway. Meclizine's effect on the growth of a human hepatocarcinoma cell line in a xenotransplantation model and on the growth of acute myeloid leukemia cells in vitro was also examined. RESULTS: Transcriptomic and metabolomic analysis of organoid development indicated that the phosphatidylethanolamine biosynthesis pathway is essential for early liver development. Unexpectedly, early hepatoblasts were selectively sensitive to the cytotoxic effect of meclizine. We demonstrate that meclizine could be repurposed for use in a new synergistic combination therapy for primary liver cancer: a glycolysis inhibitor reprograms cancer cell metabolism to make it susceptible to the cytotoxic effect of meclizine. This combination inhibited the growth of a human liver carcinoma cell line in vitro and in a xenotransplantation model, without causing significant side effects. This drug combination was also highly active against acute myeloid leukemia cells. CONCLUSION: Our data indicate that phosphatidylethanolamine biosynthesis is a targetable pathway for cancer; meclizine may have clinical efficacy as a repurposed anti-cancer drug when used as part of a new combination therapy. LAY SUMMARY: The early stages of human liver development were modeled using human hepatic organoids. We identified a pathway that was essential for early liver development. Based upon this finding, a novel combination drug therapy was identified that could be used to treat primary liver cancer and possibly other types of cancer.
BACKGROUND & AIMS: Since human induced pluripotent stem cells (iPSCs) develop into hepatic organoids through stages that resemble human embryonic liver development, they can be used to study developmental processes and disease pathology. Therefore, we examined the early stages of hepatic organoid formation to identify key pathways affecting early liver development. METHODS: Single-cell RNA-sequencing and metabolomic analysis was performed on developing organoid cultures at the iPSC, hepatoblast (day 9) and mature organoid stage. The importance of the phosphatidylethanolamine biosynthesis pathway to early liver development was examined in developing organoid cultures using iPSC with a CRISPR-mediated gene knockout and an over the counter medication (meclizine) that inhibits the rate-limiting enzyme in this pathway. Meclizine's effect on the growth of a human hepatocarcinoma cell line in a xenotransplantation model and on the growth of acute myeloid leukemia cells in vitro was also examined. RESULTS: Transcriptomic and metabolomic analysis of organoid development indicated that the phosphatidylethanolamine biosynthesis pathway is essential for early liver development. Unexpectedly, early hepatoblasts were selectively sensitive to the cytotoxic effect of meclizine. We demonstrate that meclizine could be repurposed for use in a new synergistic combination therapy for primary liver cancer: a glycolysis inhibitor reprograms cancer cell metabolism to make it susceptible to the cytotoxic effect of meclizine. This combination inhibited the growth of a humanliver carcinoma cell line in vitro and in a xenotransplantation model, without causing significant side effects. This drug combination was also highly active against acute myeloid leukemia cells. CONCLUSION: Our data indicate that phosphatidylethanolamine biosynthesis is a targetable pathway for cancer; meclizine may have clinical efficacy as a repurposed anti-cancer drug when used as part of a new combination therapy. LAY SUMMARY: The early stages of human liver development were modeled using human hepatic organoids. We identified a pathway that was essential for early liver development. Based upon this finding, a novel combination drug therapy was identified that could be used to treat primary liver cancer and possibly other types of cancer.
Authors: Shane J F Cronin; Corey Seehus; Adelheid Weidinger; Sebastien Talbot; Sonja Reissig; Markus Seifert; Yann Pierson; Eileen McNeill; Maria Serena Longhi; Bruna Lenfers Turnes; Taras Kreslavsky; Melanie Kogler; David Hoffmann; Melita Ticevic; Débora da Luz Scheffer; Luigi Tortola; Domagoj Cikes; Alexander Jais; Manu Rangachari; Shuan Rao; Magdalena Paolino; Maria Novatchkova; Martin Aichinger; Lee Barrett; Alban Latremoliere; Gerald Wirnsberger; Guenther Lametschwandtner; Meinrad Busslinger; Stephen Zicha; Alexandra Latini; Simon C Robson; Ari Waisman; Nick Andrews; Michael Costigan; Keith M Channon; Guenter Weiss; Andrey V Kozlov; Mark Tebbe; Kai Johnsson; Clifford J Woolf; Josef M Penninger Journal: Nature Date: 2018-11-07 Impact factor: 49.962
Authors: Zhen Fan Yang; Patricia Ngai; David W Ho; Wan Ching Yu; Michael N P Ng; Chi Keung Lau; Mandy L Y Li; Ka Ho Tam; Chi Tat Lam; Ronnie T P Poon; Sheung Tat Fan Journal: Hepatology Date: 2008-03 Impact factor: 17.425
Authors: Benjamin D Hopkins; Chantal Pauli; Xing Du; Diana G Wang; Xiang Li; David Wu; Solomon C Amadiume; Marcus D Goncalves; Cindy Hodakoski; Mark R Lundquist; Rohan Bareja; Yan Ma; Emily M Harris; Andrea Sboner; Himisha Beltran; Mark A Rubin; Siddhartha Mukherjee; Lewis C Cantley Journal: Nature Date: 2018-07-04 Impact factor: 49.962
Authors: Daniel T Montoro; Adam L Haber; Moshe Biton; Vladimir Vinarsky; Brian Lin; Susan E Birket; Feng Yuan; Sijia Chen; Hui Min Leung; Jorge Villoria; Noga Rogel; Grace Burgin; Alexander M Tsankov; Avinash Waghray; Michal Slyper; Julia Waldman; Lan Nguyen; Danielle Dionne; Orit Rozenblatt-Rosen; Purushothama Rao Tata; Hongmei Mou; Manjunatha Shivaraju; Hermann Bihler; Martin Mense; Guillermo J Tearney; Steven M Rowe; John F Engelhardt; Aviv Regev; Jayaraj Rajagopal Journal: Nature Date: 2018-08-01 Impact factor: 49.962
Authors: Naama Kanarek; Heather R Keys; Jason R Cantor; Caroline A Lewis; Sze Ham Chan; Tenzin Kunchok; Monther Abu-Remaileh; Elizaveta Freinkman; Lawrence D Schweitzer; David M Sabatini Journal: Nature Date: 2018-07-11 Impact factor: 49.962